StockNews.com began coverage on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Rating) in a research report sent to investors on Thursday. The brokerage issued a buy rating on the biopharmaceutical company’s stock. A number of other brokerages have also commented on ALNY. Canaccord Genuity Group lowered their price target on Alnylam Pharmaceuticals from $310.00 to […]
Sectoral Asset Management Inc. lifted its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating) by 0.6% in the 4th quarter, Holdings Channel.com reports. The firm owned 22,810 shares of the biopharmaceutical company’s stock after purchasing an additional 130 shares during the quarter. Sectoral Asset Management Inc.’s holdings in Alnylam Pharmaceuticals were worth $5,421,000 at […]
Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating) have received an average rating of “Moderate Buy” from the twenty-four research firms that are currently covering the firm, MarketBeat Ratings reports. Six investment analysts have rated the stock with a hold recommendation and sixteen have assigned a buy recommendation to the company. The average 12-month […]
StockNews.com began coverage on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Rating) in a research note released on Thursday morning. The firm issued a buy rating on the biopharmaceutical company’s stock. Other equities analysts also recently issued reports about the stock. Sanford C. Bernstein began coverage on shares of Alnylam Pharmaceuticals in a research note […]
Treasurer of the State of North Carolina grew its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating) by 2.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 86,367 shares of the biopharmaceutical company’s stock after buying an […]